US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

43.20

-0.2605-0.60%

Volume:2K

Turnover:98.82K

Market Cap:119.95M

PE:- -

High:43.93

Open:43.78

Low:43.20

Close:43.46

52wk High:48.78

52wk Low:29.31

Shares:2.78M

Float Shares:2.78M

Volume Ratio:1.17

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Travere Therapeutics announces FILSPARI data presentations at ASN Kidney Week

Travere Says Phase 2 Spartan Final Analysis Shows 75% Complete Proteinuria Remission with Filspari in IgA Nephropathy

Veeva supporting transformation of medicine through AI, Barron’s reports

Guardant Health price target raised to $200 from $190 at Guggenheim

Spyre Therapeutics Inc : Jonestrading Raises Target Price to $130 from $121

THOMSON REUTERS

Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial

Spyre Therapeutics Shares up 6.4% After Merck's Experimental Drug Succeeds in Skin Disease Trial

THOMSON REUTERS

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

EBR Systems advances FDA approval process for new WiSE manufacturing site

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)

Guardant Health (GH) Receives a Buy from Bernstein

LivaNova (LIVN) Looks Mispriced Following A Pullback In A Stronger Long Term Story

Simply Wall St.

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

LivaNova to Discuss Third-Quarter 2026 Results on Conference Call

LivaNova to Announce Third-Quarter 2026 Results

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/LFSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":43.195,"timestamp":1790967952421,"preClose":43.4555,"halted":0,"volume":2263,"delay":0,"changeRate":-0.005994638193094094,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Trading","change":-0.2605,"latestTime":"10-02 15:17:22 EDT","open":43.775,"high":43.93,"low":43.195,"amount":98820.604795,"amplitude":0.016914,"askPrice":43.28,"askSize":200,"bidPrice":43.1,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":43.4555,"sharesOutstanding":2657035,"nav":44.42,"aum":123355894.7,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.95,"preClose":43.4555,"latestTime":"19:30 EDT","volume":9,"amount":391.172,"timestamp":1790897405778,"change":0.4945,"changeRate":0.011379,"amplitude":0},"volumeRatio":1.17413},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.17413,"shares":2777035,"dividePrice":0,"high":43.93,"amplitude":0.016914,"preClose":43.4555,"low":43.195,"week52Low":29.3143,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":43.195,"eps":0,"divideRate":0,"volume":2263,"delay":0,"ttmEps":0,"open":43.775,"prevYearClose":36.6147,"prevWeekClose":44.4638,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":44.4638,"twentyDayClose":46.1466,"sixtyDayClose":47.375},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672971031","title":"Travere Therapeutics announces FILSPARI data presentations at ASN Kidney Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2672971031","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672971031?lang=en_us&edition=fundamental","pubTime":"2026-10-02 22:05","pubTimestamp":1790949928,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) will share nine new data presentations, including five oral presentations, at the American Society of Nephrology Kidney...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-announces-filspari-data-presentations-at-asn-kidney-week-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-announces-filspari-data-presentations-at-asn-kidney-week-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVTX","LENZ","BK4539","FFTY","LFSC","BK4007","BK4139","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672071710","title":"Travere Says Phase 2 Spartan Final Analysis Shows 75% Complete Proteinuria Remission with Filspari in IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2672071710","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672071710?lang=en_us&edition=fundamental","pubTime":"2026-10-02 22:00","pubTimestamp":1790949647,"startTime":"0","endTime":"0","summary":"Travere says Phase 2 SPARTAN final analysis shows 75% complete proteinuria remission with FILSPARI in IgA nephropathyTravere Therapeutics flagged nine new data presentations on FILSPARI for IgA nephro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLbtFSRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","TVTX","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672579387","title":"Veeva supporting transformation of medicine through AI, Barron’s reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2672579387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672579387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:55","pubTimestamp":1790859332,"startTime":"0","endTime":"0","summary":"AI holds the promise to accelerate drug development, optimize clinical trials, and bring lifesaving therapies to market faster, and Veeva (VEEV) Sy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veeva-supporting-transformation-of-medicine-through-ai-barrons-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veeva-supporting-transformation-of-medicine-through-ai-barrons-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","BK4534","LU0058720904.USD","VEEV","AGIX","VTHR","LU0106261372.USD","LU1989764748.USD","AIPO","EKG","BK4504","GDOC","ARTY","QTOC","LFSC","FBT","BK4588","BK4613","LU1989764664.SGD","LU0170899867.USD","LU0289739699.SGD","NVIB","BMED","MEDX","LGHT","BK4585","LU0006306889.USD","CHAT","IDNA","BK4528","HYLG","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672520357","title":"Guardant Health price target raised to $200 from $190 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672520357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672520357?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:37","pubTimestamp":1790858259,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Guardant Health (GH) to $200 from $190 and keeps a Buy rating on the shares. The firm adjusted its mod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","GDOC","FFOX","LFSC","LU0109394709.USD","LU0320765992.SGD","BK4585","BK4196","HELX","BK4551","PTH","GNMX","GH","BK4535","EKG","GNOM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672548717","title":"Spyre Therapeutics Inc : Jonestrading Raises Target Price to $130 from $121","url":"https://stock-news.laohu8.com/highlight/detail?id=2672548717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672548717?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:40","pubTimestamp":1790854836,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672983731","title":"Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672983731","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672983731?lang=en_us&edition=fundamental","pubTime":"2026-10-01 12:18","pubTimestamp":1790828280,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an announcement. Arovella Therapeutics is advancing an iNKT cell therapy platform aimed at...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arovella-nears-first-patient-dosing-in-pivotal-ala-101-cell-therapy-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arovella-nears-first-patient-dosing-in-pivotal-ala-101-cell-therapy-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALA","GNOM","IBBQ","TBXU","LFSC","IBB","CNCR","BK4588","LABX","SYNB","BK4585","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671783151","title":"Spyre Therapeutics Shares up 6.4% After Merck's Experimental Drug Succeeds in Skin Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671783151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671783151?lang=en_us&edition=fundamental","pubTime":"2026-09-30 22:56","pubTimestamp":1790780218,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M1BP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671150783","title":"Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671150783","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671150783?lang=en_us&edition=fundamental","pubTime":"2026-09-30 22:56","pubTimestamp":1790780215,"startTime":"0","endTime":"0","summary":"BUZZ-Spyre gains after Merck's drug succeeds in skin disease trial** Shares of Spyre TherapeuticsSYRE.Orise 6.08% to $89.87** Merck'sMRK.Nexperimental drug tulisokibartsignificantly reducesinflammator","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M1CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU1057294990.SGD","SG9999002232.USD","MRK","LU1291159041.SGD","BK4559","BMED","SG9999001440.SGD","LU1983299246.USD","LU0208291251.USD","IE00BLSP4239.USD","LU0861579265.USD","LU2361044865.SGD","LU1430594728.SGD","LU2324357040.USD","LU0238689110.USD","LU1989771016.USD","LU1066051811.HKD","LU0965508806.USD","LU0203345920.USD","LU1061106388.HKD","LU0265550359.USD","LU1923622614.USD","BK4534","LU0266013472.USD","LU0985320562.USD","LU0320765646.SGD","LU1571399168.USD","LU2461242641.AUD","LU0980610538.SGD","LU1066053197.SGD","LU0234572021.USD","LU1037948897.HKD","LU2125909247.SGD","LU0689626769.HKD","LU0942090050.USD","LU0823416689.USD","LU2023250504.SGD","LU1929549753.HKD","LU1093756168.USD","LU2106854487.HKD","LU0472753341.HKD","LU0868494708.USD","LU0965509010.AUD","LU0057025933.USD","PAWZ","LU1066051498.USD","BK4516","LU0006306889.USD","BK4139","FTXH","IE00BFTCPJ56.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","LU0070302665.USD","LU0289739343.SGD","LU1585245621.USD","LU2089984988.USD","JDOC","SG9999002224.SGD","LU1989772840.SGD","LU1941712264.USD","LU2361045086.USD","LFSC","IE00BSNM7G36.USD","LU2023250843.SGD","LU1974910355.USD","LU0965509101.SGD","LU0130102774.USD","IE00BN8TJ469.HKD","SG9999015358.SGD","SG9999014542.SGD","LU1934455863.HKD","LU0211331839.USD","LU0289739699.SGD","LU2125154935.USD","IYH","LU1093756325.SGD","LU1116320737.USD","LU2125909593.SGD","LU0432979614.USD","HRTS","SYRE","SG9999014575.USD","LU1201861249.SGD","XLV","LU1989772923.USD","RXL","LU0868494617.USD","LU0162691827.USD","LU1917777945.USD","LU0072461881.USD","SG9999013999.USD","LU0069063385.USD","LU2491049909.HKD","IE00B1BXHZ80.USD","SG9999001176.SGD","LU0058720904.USD","LU0265550946.USD","LU1934455277.USD","IE00BBT3K403.USD","LU2468319806.SGD","LU1941712348.USD","TRUH","LU0477156953.USD","IE0009355771.USD","BK4550","IXJ","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0124676726.USD","SG9999014559.SGD","SG9999014567.USD","SGXZ57979304.SGD","SG9999015341.SGD","LU1069347547.HKD","LU1934455194.USD","BK4588","LU0965509283.SGD","LU1066051225.USD","LU1162221912.USD","LU0289961442.SGD","LU2360032135.SGD","LU1037948541.HKD","SG9999001176.USD","GDOC","LU1699723380.USD","FHLC","LU0859254822.USD","LU1032466523.USD","LU0203347892.USD","LU2357627491.SGD","BK4007","BK4533","LU0122379950.USD","LU2491050071.SGD","LU0130517989.USD","LU1116320901.HKD","LU1023059063.AUD","LU2361044949.HKD","LU2125154778.USD","LU0320765489.SGD","VHT","LU0648001328.SGD","IE00BLSP4452.SGD","IHE","LU2491050154.USD","PPH","LU2433249047.HKD","BK4585","LU0511384066.AUD","LU1035773651.USD","IE000M9KFDE8.USD","IE00BJJMRZ35.SGD","LU0098860793.USD","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671520485","title":"MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671520485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671520485?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:10","pubTimestamp":1790770233,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced that its clinical-stage agenT-797 iNKT platform has been selected as a therapeutic cell system within an Advance...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-selected-for-arpa-h-funded-initiative-to-advance-room-temp-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-selected-for-arpa-h-funded-initiative-to-advance-room-temp-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","CNCR","LFSC","IBB","IBBQ","GNOM","BK4585","BK4588","TBXU","BK4139","FBT","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","NVIB","PSCH","TECB","MEDI","LU2324357040.USD","BK4007","TEVA","BK4585","BMED","IEIH","LU1983299246.USD","BK4559","IYH","MRNX","MRNY","BK4584","SYNB","BK4596","GNMX","IBB","BK4557","BBP","LABU","RSPH","BK4588","BK4566","GDOC","TBXU","FRTY","PINK","LFSC","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","NVIB","PSCH","TECB","MEDI","BK4007","TBPH","BK4585","BMED","IEIH","IYH","MRNX","MRNY","SYNB","GNMX","IBB","BBP","LABU","RSPH","BK4588","GDOC","TBXU","FRTY","PINK","LFSC","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","NVIB","PSCH","TECB","MEDI","BK4585","BMED","IEIH","IYH","MRNX","MRNY","SYNB","GNMX","IBB","BBP","LABU","RSPH","BK4588","GDOC","TBXU","EES","FRTY","PINK","LFSC","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670740486","title":"Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670740486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670740486?lang=en_us&edition=fundamental","pubTime":"2026-09-28 05:30","pubTimestamp":1790544629,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE). Oncolyti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oncolytics-biotech-oncy-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oncolytics-biotech-oncy-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","BK4588","BK4137","LABU","BK4581","LU0128526141.USD","ONCY","LU0029874061.USD","BK4585","LFSC","XLV","HCSG","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670745514","title":"Guardant Health (GH) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2670745514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670745514?lang=en_us&edition=fundamental","pubTime":"2026-09-26 22:15","pubTimestamp":1790432125,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Guardant Health, with a price target of $210.00. The company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guardant-health-gh-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guardant-health-gh-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","GH","FFOX","LU0320765992.SGD","GNOM","HELX","BK4551","EKG","GNMX","LFSC","PTH","BK4588","BK4585","GDOC","LU0109394709.USD","BK4535","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670415345","title":"LivaNova (LIVN) Looks Mispriced Following A Pullback In A Stronger Long Term Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2670415345","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670415345?lang=en_us&edition=fundamental","pubTime":"2026-09-25 01:34","pubTimestamp":1790271287,"startTime":"0","endTime":"0","summary":"LivaNova (LIVN) is back on investor radar after recent share moves, with the price near $77.16 and year-to-date total return around 27%, inviting closer attention to fundamentals.\nLivaNova’s recent share price softness, with the 1 month share price return down 1.41% and 3 month share price return down 4.80%, comes against a stronger backdrop. This is highlighted by a 27.24% year to date share price gain and 44.96% 1 year total shareholder return, which signals momentum has built over the past...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice2-card/1788934354473","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice2-card/1788934354473"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/livanova-livn-looks-mispriced-following-a-pullback-in-a-stro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/livanova-livn-looks-mispriced-following-a-pullback-in-a-stro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","LIVN","BK4082","LU2065171402.SGD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499070","title":"FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499070","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499070?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:52","pubTimestamp":1790261520,"startTime":"0","endTime":"0","summary":"Mizuho's Bradley Bowers thinks the boost will be substantial. He wrote Tuesday that sales doubled in the launch years of other cancer-screening products-like colon cancer stool test Cologuard from the Exact Sciences unit of Abbott, or the colon cancer blood test Shield from Guardant Health.Galleri screens a person's blood sample for bits of DNA showing features typical of cancer cells. It tells you if it has found a general signal of cancer somewhere in your body-\"Cancer Signal Detected\"-and makes its best guess at the kind of tissue where the cancer is hiding.Clinical trials showed Galleri can detect cancers for which there is no standard screen, such as cancer of the ovary or pancreas. Grail's two big clinical trials showed that it rarely tells you that you have cancer when you don't. When you do have cancer, the test finds it on average about 50% of the 60% of the time.That is good performance, compared with other widely used screens, like the mammogram. Grail plans to tell customer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4196","LFSC","BK4551","BK4082","ABT","LU0122379950.USD","TMED","LABU","LU1061106388.HKD","BK4585","LU2089984988.USD","FFOX","LU1721429402.USD","BK4588","LU1989763690.USD","SGXZ23171101.USD","LU0889565916.HKD","SG9999004303.SGD","LU2112291526.USD","BK4581","GNMX","LU1691799644.USD","SGXZ41872573.SGD","LU0868494617.USD","PJP","LU1670627923.USD","BK4568","LU0320765489.SGD","IE0002141913.USD","LU2468319806.SGD","GRAL","GH","SG9999002232.USD","EKG","HELX","LU1721429741.USD","BK4139","SG9999002224.SGD","LU2237957811.SGD","LU0289739699.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","PTH","GNOM","LU0882574055.USD","BK4535","IHI","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669770466","title":"Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669770466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669770466?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:30","pubTimestamp":1790242220,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Royalty Pharma (RPRX), Travere Therapeutics (TVTX) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-royalty-pharma-rprx-travere-therapeutics-tvtx-and-veeva-systems-veev-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-royalty-pharma-rprx-travere-therapeutics-tvtx-and-veeva-systems-veev-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VEEV","LU0128526141.USD","BK4613","LU0266013472.USD","LABU","HCSG","FFTY","BK4585","BK4528","LU0170899867.USD","PBE","TVTX","LFSC","BK4139","BK4007","BK4137","BK4167","LU1989764748.USD","BK4504","BK4581","XBI","EKG","BK4534","BK4588","LU0106261372.USD","LU0289739699.SGD","LU1989764664.SGD","LGHT","LU0006306889.USD","IHE","XLV","LU0029874061.USD","LU0058720904.USD","RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4585","PINK","NVIB","PSCH","TBXU","BK4588","IBB","MRNY","SYNB","GDOC","GNMX","BMED","XLVX","LFSC","MESO","LABU","IYH","FRTY","MEDI","TECB","RSPH","BK4139","BBP","IEIH","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669864994","title":"LivaNova to Discuss Third-Quarter 2026 Results on Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2669864994","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669864994?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:02","pubTimestamp":1790168546,"startTime":"0","endTime":"0","summary":"LivaNova to discuss third-quarter 2026 results on conference callLivaNova will release third-quarter 2026 results ahead of a conference call on Nov. 4, 2026.Results call scheduled for 1 p.m. GMT on No","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL8QDqLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065169927.USD","LIVN","LFSC","LU2065171402.SGD","BK4082","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486182","title":"LivaNova to Announce Third-Quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486182?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168406,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA55JRCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171311.SGD","LFSC","LIVN","LU2065170008.USD","BK4082","LU2065169927.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}